Cosmetic & Topical Peptides
Overview
Bioactive peptides for topical dermal research — copper matrikines, collagen-signalling matrikines and neuromodulatory anti-wrinkle peptides, plus copper-peptide and cosmetic-peptide comparison pages.
| Peptide | INCI name | Primary function | Key mechanism |
|---|---|---|---|
| GHK-Cu | Copper Tripeptide-1 | Dermal remodeling, collagen synthesis | Copper-dependent enzymatic activation, TGF-β signalling |
| Matrixyl | Palmitoyl Pentapeptide-4 | Collagen production | Matrikine (procollagen-fragment) signalling |
| Argireline | Acetyl Hexapeptide-8 | Expression-line reduction | SNARE-complex inhibition (neuromodulatory) |
| Matrixyl 3000 | Palmitoyl Tripeptide-1 + Tetrapeptide-7 | Collagen + anti-inflammatory | Dual matrikine + IL-6 modulation |
| SNAP-8 | Acetyl Octapeptide-3 | Advanced expression-line reduction | Enhanced SNARE-complex inhibition |
How Cosmetic Peptides Work
The cosmetic peptides fall into a few mechanism groups. Signal peptides — matrikines such as GHK-Cu, Matrixyl and Matrixyl 3000 — mimic extracellular-matrix fragments that tell fibroblasts to rebuild collagen and matrix. Neurotransmitter-inhibiting peptides (Argireline, SNAP-8) interfere with the SNARE complex to soften the micro-contractions behind expression lines. Carrier peptides (GHK-Cu) additionally deliver copper, a cofactor for skin-repair enzymes such as superoxide dismutase and lysyl oxidase. All are short (3–8 residues) and formulated for topical delivery through the stratum corneum.
Signal peptides — GHK-Cu, Matrixyl, Matrixyl 3000
Matrikines that signal fibroblasts to rebuild collagen and extracellular matrix.
Neurotransmitter-inhibiting — Argireline, SNAP-8
SNARE-complex inhibition softens the micro-contractions behind dynamic expression lines.
Carrier peptides — GHK-Cu
Deliver copper, a cofactor for skin-repair enzymes such as SOD and lysyl oxidase.
Key Properties at a Glance
| Peptide | CAS number | MW (Da) | Length | logP | Stability |
|---|---|---|---|---|---|
| GHK-Cu | 89030-95-5 | ≈ 403.9 | 3 aa | −2.5 | Stable in solution |
| Matrixyl | 214047-00-4 | 802.06 | 5 aa | 3.8 | Stable in formulation |
| Argireline | 616204-22-9 | 888.47 | 6 aa | −1.7 | Stable in solution |
| Matrixyl 3000 | 147732-56-7 / 221227-05-0 | 673.8 + 520.7 | 3 + 4 aa | 4.0 / 3.8 | Stable in formulation |
| SNAP-8 | 868802-72-6 | 1074.30 | 8 aa | −1.9 | Stable in solution |
Research Evidence
Preclinical research highlights (qualitative — see each compound page for detail):
| Peptide | Reported finding | Reference |
|---|---|---|
| GHK-Cu | Stimulates type I/III collagen and glycosaminoglycan synthesis in fibroblasts | Maquart FX et al., 1993 |
| Matrixyl | Upregulates procollagen I and III expression in fibroblasts | Katayama K et al., 1993 |
| Argireline | Reduces neurotransmitter release via SNARE inhibition in neuronal models | Blanes-Mira C et al., 2002 |
| Matrixyl 3000 | Collagen stimulation plus IL-6 reduction in aged fibroblasts | cosmetic-peptide literature |
| SNAP-8 | Reduced muscle-contraction amplitude vs control | SNAP-8 literature |
Clinical research highlights (topical human studies):
| Peptide | Study context | Reference |
|---|---|---|
| GHK-Cu | Topical cream — fine lines and skin-density research | dermatology literature |
| Matrixyl | Topical — wrinkle-depth / volume research | Robinson LR et al., 2005 |
| Argireline | Topical — wrinkle-roughness research | Blanes-Mira C et al., 2002 |
| Matrixyl 3000 | Topical cream — wrinkle-volume research | Gorouhi F, Maibach HI (2009) |
| SNAP-8 | Topical — expression-line research | cosmetic-peptide literature |
Dermal Penetration
| Peptide | MW (Da) | logP | Predicted absorption | Formulation strategy |
|---|---|---|---|---|
| GHK-Cu | ≈ 403.9 | −2.5 | Low (hydrophilic) | Liposomal / penetration enhancer |
| Matrixyl | 802.06 | 3.8 | Moderate (lipophilic) | Oil-in-water emulsion |
| Argireline | 888.47 | −1.7 | Low (hydrophilic) | Liposomal / penetration enhancer |
| Matrixyl 3000 | 673.8 + 520.7 | 4.0 / 3.8 | Moderate | Emulsion |
| SNAP-8 | 1074.30 | −1.9 | Low (hydrophilic) | Liposomal / peptide carrier |
Formulation Considerations
| Factor | Recommendation |
|---|---|
| pH range | 5.0–7.0 (skin-compatible) |
| Temperature stability | Stable up to ~40°C in formulation |
| Oxidation protection | Antioxidants (vitamin E, BHT) |
| Preservation | Broad-spectrum preservative system |
| Penetration enhancers | Transcutol, ethoxydiglycol, liposomes |
| Typical use concentration | 0.001–10% (peptide-dependent) |
Selected References
- Maquart FX, et al. Stimulation of collagen synthesis by the tripeptide–copper complex GHK-Cu. FEBS Letters, 1993.
- Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular-matrix production. Journal of Biological Chemistry, 1993.
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 2002.
- Robinson LR, et al. Topical palmitoyl pentapeptide for photoaged skin. International Journal of Cosmetic Science, 2005.
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
